FDA
label_change
· 2022-04-14
FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
Summary
FDA approved Janssen's supplemental application for SYMTUZA, updating its labeling for the fixed-dose combination of darunavir, cobicistat, emtricitabine, and t…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for SYMTUZA (DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)